Retatrutide
Fat LossWeight Loss / Metabolic
Triple receptor agonist for obesity research.
For research use only.
Key Facts
- CAS
- Not available
- Molecular Weight (MW)
- 4845.4 g/mol
- Half-life
- ~120 hours (~5 days)
- Unit
- mg
- Administration Route
- Subcutaneous
- Frequency
- Weekly
- Last updated
- 12/18/2025
- Targets
- GLP-1/GIP/Glucagon receptors
Overview
Triple receptor agonist for obesity research.
Protocol
- Dosage Range
- 0.5-12 mg weekly
- Frequency
- Weekly
- Cycle
- Ongoing for weight management
- Administration Route
- Subcutaneous
- Reconstitution Guide
- Varies
Science
Mechanism of Action
Appetite suppression, energy expenditure increase.
Targets
GLP-1/GIP/Glucagon receptors
Studies
- — Journal/year not available
Benefits
Weight lossInsulin sensitivityMetabolic health
Potential Side Effects
- Nausea
- Vomiting
- Diarrhea